Treatment-Resistant Depression (TRD) Dosing and Administration Overview1

TRD Dosing Frequency and Strengths Are Flexible1

  • SPRAVATO® is administered by the patient at a certified treatment center where the patient is monitored by a healthcare provider for at least two hours

SPRAVATO® offers the freedom to choose your treatment approach1

Start with 56 mg or 84 mg, alone or in combination with an oral AD, and an individualized dosing schedule

Treatment-Resistant Depression (TRD) Dosing and Administration chart
Treatment-Resistant Depression (TRD) Dosing and Administration chart

Start with 56 mg or 84 mg

  • If clinically warranted, you may start a patient on SPRAVATO® alone — without the need to combine it with an oral AD
  • SPRAVATO® now offers more flexibility in treatment approach, dosing, and post-induction frequency
  • Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment
injection dosing spray

AD=antidepressant.

injection dosing spray

AD=antidepressant.

Check mark orange icon

Administration

SPRAVATO® is the only FDA-approved treatment used alone or in combination with an oral antidepressant for patients with MDD having an inadequate response to at least 2 oral antidepressants1

Monitoring & Discharge

  • To ensure safe and appropriate use, SPRAVATO® nasal spray is administered only at REMS-certified treatment centers
  • After taking SPRAVATO®, patients are monitored and evaluated by a healthcare provider for at least 2 hours until patients are safe to leave
  • Respiratory status (including pulse oximetry) should be monitored at each treatment session
  • Blood pressure should be monitored prior to and 40 minutes after administration and subsequently as clinically warranted until values remain consistent at a safe level and the treatment session ends
  • Patients should coordinate a ride home after treatment, as they should not drive or operate heavy machinery until the next day, following a restful night’s sleep

Careful consideration is advised prior to treatment of individuals with a history of substance use disorder, including alcohol. Monitoring for signs of abuse and dependence is recommended.

AD=antidepressant; MDD=major depressive disorder; REMS=Risk Evaluation and Mitigation Strategy.

References:

  1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.
VIEW FULL IMPORTANT SAFETY INFORMATIONisi-icon